80wk Downtrend — falling+below (sma 21.02 vs px 16.71)
200wk Downtrend — falling+below (sma 48.08 vs px 16.71)
Funds Distributing — momZ +0.29 · 0.61→0.56
Short Attack — velZ +0.98 · age 4w×1.00 · 4.65%
Earnings Headwind — ER in 24.154d · w1 med -2.5% (mag 1/3) · winRate 34.3% (rel 2/3) · n35
RS Breakdown — momZ +0.22 · low 28w×0.73 · vs industry
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. Read full Trend Edge analysis →
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: January 2, 2018
Headquarters: 40 Guest Street, Boston, MA, United States, 02135
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$28.06
Near-term / short-term trend
Weekly
40-Week SMA
$21.45
Medium-term trend
Weekly
80-Week SMA
$21.02
Cyclical trend (business cycle)
Weekly
200-Week SMA
$48.08
Secular trend (multi-year)
Monthly
10-Month SMA
$18.85
Near-term monthly trend
Monthly
20-Month SMA
$19.83
Medium-term monthly trend
Monthly
40-Month SMA
$37.19
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$5.80
support
8.02x
5 months ago
$49.00
resistance
1.30x
22 months ago
Historical Earnings Reactions (35 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
-0.12%
0.55%
51.43%
4.49%
-8.92%
1 Day
-0.86%
-0.07%
45.71%
19.74%
-20.37%
1 Week
-4.63%
-2.45%
34.29%
31.45%
-32.22%
2 Weeks
-5.54%
-6.39%
34.29%
18.77%
-27.67%
1 Month
-1.42%
-6.33%
40.00%
94.23%
-38.62%
Next earnings: November 11, 2026 (23 days away)
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
5.1%
62.5%
8
Feb
-5.7%
33.3%
9
Mar
-6.3%
22.2%
9
Apr
18.6%
55.6%
9
May
5.4%
44.4%
9
Jun
-5.1%
33.3%
9
Jul
-9.8%
33.3%
9
Aug
-2.3%
44.4%
9
Sep
-4.3%
44.4%
9
Oct
7.5%
50.0%
8
Nov
7.5%
62.5%
8
Dec
-8.3%
37.5%
8
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
0.15%
48.3%
414
Tuesday
-0.18%
43.8%
454
Wednesday
0.41%
49.9%
451
Thursday
-0.26%
42.8%
444
Friday
0.29%
44.6%
442
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 22.8%
Insider Transactions — Smart Summary
Total insider ownership: 15.2%
Founder-led management: Ronald Seidel (Co-Founder)
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Cue Biopharma
(CUE) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.